Expanding Manufacturing Capacity Halo Pharma’s recent facility expansion in Mirabel, Quebec, and the addition of new sterile manufacturing capabilities, including a high-speed filling line, present opportunities to collaborate on sterile injectables and injectable drug products, targeting clients seeking reliable high-volume production.

Focus on Sterile Products The company’s emphasis on developing and manufacturing BFS sterile products across diagnostic, respiratory, ophthalmic, topical, otic, and oral categories indicates a strong demand for specialized sterile solutions, making them a prime partner for healthcare companies seeking advanced sterile manufacturing services.

Strategic Industry Alliances Halo Pharma’s partnership with Noramco and Purisys within the Noramco Group creates a comprehensive North American supply chain for APIs and drug products, offering potential opportunities to integrate services or co-develop products for clients looking for end-to-end supply chain solutions.

Leadership & Innovation The recent appointment of a new CEO and a Site Director for cGMP operations signifies a focus on leadership-driven growth and operational excellence, enabling the company to attract partnerships with innovator pharmaceutical companies and contract developers aiming for scalable manufacturing solutions.

Market Expansion & Outreach Participation in industry events like DCAT Week and ongoing facility developments suggest Halo Pharma’s active effort to increase market visibility and client engagement, providing sales teams with opportunities to connect with potential customers in need of reliable, scalable manufacturing partnerships in North America.